BACKGROUND: Aim of this study was to evaluate the outcomes of endocarditis patients undergoing valve surgery with the Cytosorb® hemoadsorption (HA) device during cardiopulmonary bypass. METHODS: From 2009 until 2019, 241 patients had undergone valve surgery due to endocarditis at the Department of Cardiac Surgery, University Hospital of Basel. We compared patients who received HA during surgery (n = 41) versus patients without HA (n = 200), after applying inverse probability of treatment weighting. RESULTS: In-hospital mortality, major adverse cardiac and cerebrovascular events and postoperative renal failure were similar in both groups. Demand for norepinephrine (88.4 vs. 52.8%; p = 0.001), milrinone (42.2 vs. 17.2%; p = 0.046), red blood cell concentrates (65.2 vs. 30.6%; p = 0.003), and platelets (HA vs. Control: 36.7 vs. 9.8%; p = 0.013) were higher in the HA group. In addition, a higher incidence of reoperation for bleeding (34.0 vs. 7.7 %; p = 0.011), and a prolonged length of in-hospital stay (15.2 (11.8 to 19.6) vs. 9.0 (7.1 to 11.3) days; p = 0.017) were observed in the HA group. CONCLUSIONS: No benefits of HA-therapy were observed in patients with infective endocarditis undergoing valve surgery.
BACKGROUND: Aim of this study was to evaluate the outcomes of endocarditispatients undergoing valve surgery with the Cytosorb® hemoadsorption (HA) device during cardiopulmonary bypass. METHODS: From 2009 until 2019, 241 patients had undergone valve surgery due to endocarditis at the Department of Cardiac Surgery, University Hospital of Basel. We compared patients who received HA during surgery (n = 41) versus patients without HA (n = 200), after applying inverse probability of treatment weighting. RESULTS: In-hospital mortality, major adverse cardiac and cerebrovascular events and postoperative renal failure were similar in both groups. Demand for norepinephrine (88.4 vs. 52.8%; p = 0.001), milrinone (42.2 vs. 17.2%; p = 0.046), red blood cell concentrates (65.2 vs. 30.6%; p = 0.003), and platelets (HA vs. Control: 36.7 vs. 9.8%; p = 0.013) were higher in the HA group. In addition, a higher incidence of reoperation for bleeding (34.0 vs. 7.7 %; p = 0.011), and a prolonged length of in-hospital stay (15.2 (11.8 to 19.6) vs. 9.0 (7.1 to 11.3) days; p = 0.017) were observed in the HA group. CONCLUSIONS: No benefits of HA-therapy were observed in patients with infective endocarditis undergoing valve surgery.
Authors: Mingchen Song; James Winchester; Robert L Albright; Vincent J Capponi; Michael D Choquette; John A Kellum Journal: Blood Purif Date: 2004-08-13 Impact factor: 2.614
Authors: Christopher H Cabell; Elias Abrutyn; Vance G Fowler; Bruno Hoen; Jose M Miro; G Ralph Corey; Lars Olaison; Paul Pappas; Kevin J Anstrom; Judith A Stafford; Susannah Eykyn; Gilbert Habib; Carlos A Mestres; Andrew Wang Journal: Am Heart J Date: 2005-11 Impact factor: 4.749
Authors: Todd C Crawford; J Trent Magruder; Joshua C Grimm; Alejandro Suarez-Pierre; Christopher M Sciortino; Kaushik Mandal; Kenton J Zehr; John V Conte; Robert S Higgins; Duke E Cameron; Glenn J Whitman Journal: Ann Thorac Surg Date: 2016-11-22 Impact factor: 4.330
Authors: T Mihaljevic; M Tönz; L K von Segesser; M Pasic; P Grob; J Fehr; B Seifert; M Turina Journal: J Thorac Cardiovasc Surg Date: 1995-06 Impact factor: 5.209
Authors: Gilbert Habib; Patrizio Lancellotti; Manuel J Antunes; Maria Grazia Bongiorni; Jean-Paul Casalta; Francesco Del Zotti; Raluca Dulgheru; Gebrine El Khoury; Paola Anna Erba; Bernard Iung; Jose M Miro; Barbara J Mulder; Edyta Plonska-Gosciniak; Susanna Price; Jolien Roos-Hesselink; Ulrika Snygg-Martin; Franck Thuny; Pilar Tornos Mas; Isidre Vilacosta; Jose Luis Zamorano Journal: Eur Heart J Date: 2015-08-29 Impact factor: 29.983
Authors: John A Kellum; Ramesh Venkataraman; David Powner; Michele Elder; Georgene Hergenroeder; Melinda Carter Journal: Crit Care Med Date: 2008-01 Impact factor: 7.598
Authors: George O Angheloiu; Gabriel B Gugiu; Cristian Ruse; Rishikesh Pandey; Ramachandra R Dasari; Carl Whatling Journal: JACC Basic Transl Sci Date: 2017-04-24
Authors: Mehdi Javanbakht; Miranda Trevor; Mohsen Rezaei Hemami; Kazem Rahimi; Michael Branagan-Harris; Fabian Degener; Daniel Adam; Franziska Preissing; Jörg Scheier; Suzanne F Cook; Eric Mortensen Journal: Pharmacoecon Open Date: 2020-06
Authors: Jurij Matija Kalisnik; Spela Leiler; Hazem Mamdooh; Janez Zibert; Thomas Bertsch; Ferdinand Aurel Vogt; Erik Bagaev; Matthias Fittkau; Theodor Fischlein Journal: J Clin Med Date: 2022-07-07 Impact factor: 4.964